Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Canakinumab (Ilaris) is indicated for the treatment of periodic fever syndromes and gout flares in specific patient populations.
• The information was derived from 16 systematic reviews/meta-analyses studies.
• In treating gout flares, canakinumab showed superior effectiveness compared to standard treatments like NSAIDs and colchicine, with a favorable safety profile primarily in adult patients.
• For Familial Mediterranean Fever (FMF), canakinumab achieved up to 81% complete remission in pediatric patients, showing high effectiveness alongside Anakinra; adverse events were slightly higher in adults than children.
• Canakinumab demonstrated significant efficacy across various immune-mediated diseases such as CAPS, FMF, sJIA, and other IL-1 mediated conditions while being generally well-tolerated but associated with some respiratory infections and gastrointestinal issues.
• During pregnancy studies involving inflammatory disease treatments with canakinumab or anakinra, most babies were born healthy despite some preterm births; the focus was on safety rather than effectiveness.
• In Schnitzler syndrome cases reviewed across seven publications involving 34 patients, canakinumab provided a complete response rate of 58.6%, though infections were noted as frequent adverse events among this population group.
• For systemic juvenile idiopathic arthritis (sJIA), meta-analysis revealed that canakinumab had the highest probability of efficacy compared to other biologics like Anakinra or Tocilizumab without significant differences in serious adverse events between these treatments.